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Background & Objective: Pain is the most common side effect of induced medical
abortion. However, the optimal analgesia method remains as a clinical challenge.
This study aimed to compare the efficacy of two methods of administration of
diclofenac as a prophylactic or a therapeutic in pain management in induced secondtrimester medical abortion.
Materials & Methods: This randomized clinical trial study was conducted upon pregnant
women who were candidates for induced medical abortion and referred to a tertiary
educational hospital between October 2019 and December 2020. Participants were divided
into two groups based on the mode of diclofenac administration, which was either
simultaneously with the first dose of misoprostol or after beginning of the pain. Pain severity,
induction-to-abortion time interval, total misoprostol dosage, Hemoglobin concentration,
length of hospitalization, and size of retained pregnancy products by ultrasound, and the
cumulative dose of opioid usage were compared between the groups.
Results: The severity of pain which was measured by a visual analog scale (VAS),
residual of conceived products, hospitalization days, and the total misoprostol dosage were
significantly lower (P<0.05) in the prophylaxis compared to the treatment group.
Conclusion: Simultaneous administration of diclofenac with misoprostol as
prophylactic method of pain management may be an optimal method in induced
medical abortion in the second trimester.
Keywords: Analgesia, Diclofenac, Medical abortion, Misoprostol, Pain management
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Introduction
Medical abortion is an acceptable and safe method
for pregnancy termination (1, 2) and in the second
trimester it could be performed with a minimally invasive method via vaginal delivery of the conception
products (3, 4). Misoprostol is one of the most commonly used agents for medical abortion due to its high
efficacy, easy storage and handling, and low cost (5, 6).
Pain is the most common side effect of induced
medical abortion (7, 8). Women usually experience
moderate to severe pain during medical abortion,
ranging from 6 to 8 in a 10-point scale as maximum
pain scores (9). During the induced medical abortion,
pain intensity increases as the fetus pass through the
cervical canal (10); therefore, analgesia requirement
increases due to higher gestational age and longer
induction-to-abortion interval (11).
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To achieve high-quality pain management, health
professionals must provide appropriate, safe, and
effective pain relief options. Although local clinical
practice guidelines have been widely developed in
many countries, there are few studies about pain management recommendations for induced abortion.
In the past studies, narcotics (12), pregabalin (13), as
well as various non-steroidal anti-inflammatory drugs
(NSAIDs) regimens (7, 14), as prophylactic (starting
before abortion induction) or therapeutic (starting after
the onset of pain) were administered for pain management. Hence, the optimal method and timing of
analgesics for pain management are still unclear (3, 7).
This study aimed to compare the efficacy of prophylactic diclofenac (administered simultaneously with
sublingual misoprostol) with therapeutic diclofenac
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(administered upon pain onset) in pain management
during the induced second-trimester medical abortion.

Materials and Methods
Study overview
In this clinical trial study, the participants who were
candidate for induced second-trimester medical abortion were recruited. This study was performed between
October 2019 and December 2020 in a tertiary referral
hospital affiliated to Tehran University of Medical
Sciences, Tehran, Iran.
The inclusion criteria were gestational age between
14 to 20 weeks, stable hemodynamic status with no
clinical signs and symptoms of pelvic infection (purulent vaginal discharge, body temperature >38ᵒC degrees, and lower abdominal tenderness) at admission
and at least two sonographies indicating fetal demise.
The exclusion criteria were the history of using of sedative, analgesic drugs or addiction or hypersensitivity to
NSAID.
A recorded visual analog scale (VAS) questionnaire
for pain assessment was assessed for all patients. VAS
is a psychometric scale for pain intensity measurement.
It is a standard 10 cm tool, the score zero at the left end
indicates no pain, and the score ten at the right end
indicates the most severe pain. Achieving a score of 13 means mild pain, 4-6 moderate pain, and 7-10
showing severe pain (15). The primary outcome of the
study was mean VAS score during the procedure and
last VAS score before the completion of termination.
Patient satisfaction with changes in pain level was
measured by a 1-5 scale, from very low to very much.
The demographic, clinical, and obstetrical data including personal information, age, gestational age, gravity, parity, previous history abortion and body mass
index were provided by each participant. Indeed, pain
severity, induction-to-abortion time interval, total
misoprostol dosage during the induction period, hemoglobin concentration changes 6 hours after complete
abortion (bleeding estimation by pad count), length of
hospitalization, pain reduction satisfaction, size of
retained pregnancy products by ultrasound, and cumulative dose of opioid usage were gathered either.
After enrolment, randomization was performed with
an allocation sequence generated by block randomization by the trial statistician. Participants were
divided into two equal groups. In all patients, medical
induction was performed with serial doses of misoprostol (400 μg), applied sublingually every four hours
for a maximum of five doses.
The prophylactic group (n=108) received 100 mg
rectal diclofenac made in Iran (Tolidaru Company)
simultaneously with the first dose of misoprostol as a
prophylactic, and the therapeutic group (n=112) received the same dose of diclofenac upon pain onset or
four hours after misoprostol. In both groups, diclofenac
Volume 7, January-February 2022

was administered every 12 hours as patient request.
Pethidine was infused intravenously in a bolus dose of
25 mg maximum to four doses for pain reduction when
there was no response to diclofenac (VAS score 7-10).
After completing the abortion, a transvaginal ultrasound was performed to confirm a successful medically induced abortion. All ultrasound scans were performed by the same radiologist. A complete blood
count was obtained before and after medical abortion.
All patients were admitted in labor with continuous
monitoring for vital sign and bleeding. Any complication during the admission was recorded and managed as possible.
Ethical Consideration
The protocol of the study was approved and registered by the ethical committee of Tehran University of
Medical Sciences with reference code IR.TUMS.MEDICINE.REC.1398.201. Participants then submitted a written consent form to attend the trial. This trial
was conducted in agreement with the principles of the
Helsinki Declaration.
Statistical Analysis
The data were analyzed by SPSS 20.0 (SPSS Inc.,
Chicago, IL., USA). Independent-Sample-T, Chi-Square, Kolmogorov-Smirnov, and Fisher Exact tests were
used. The statistical significance for all outcomes was
set at P-value less than 0.05.

Results
The mean age, gestational age and the body mass
index in both groups were not significantly different
(Table 1). The used diclofenac doses were not
significantly different (P=0.801) in groups either.
Although the induction-to-abortion time, cumulative
dose of misoprostol, length of hospitalization, and pain
severity were significantly lower in prophylactic
group, there were no significant differences in terms of
the size of the retained pregnancy products (P=0.350)
and blood loss (P=0.130). The post-induction
characteristics of the participants in each group are
compared in Table 2.
IV opioid analgesics were indicated for pain relief in
27 patients in prophylaxis group, and the pain was
successfully subsided by a single dose of 25 mg of
pethidine, whereas it was indicated in 43 patients in
therapeutic group. The pain was subsided by an IV
bolus injection of 25 mg of pethidine in 34 patients and
a cumulative dose of 50 mg IV pethidine in the other
nine patients. Therefore, patients in prophylaxis group
achieved pain relief with non-opioid analgesics, more
frequently. They also had experienced pain relief with
less IV pethidine infusion in comparison with
therapeutic group (Table 3).
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Table 1. Demographic characteristics of the participants in each group
Prophylactic diclofenac
(Mean±SD)
30.8±7.4

Therapeutic diclofenac
(Mean±SD)
29.7±5.4

Body mass index (kg/m2)

27.8±1.77

27.4±1.7

0.524

Gestational age (week)

16.7±1.5

16.9±1.5

0.540

Characteristics
Age (year)

P-value
0.664

SD: standard deviation

Table 2. Post-induction characteristics of the participants in each group
Prophylactic diclofenac
(Mean±SD)
12.15±3.3

Therapeutic diclofenac
(Mean±SD)
13.4±3.9

P<0.001

Hospitalization (days)

2.64±0.7

3.27±0.9

P<0.001

Pain intensity (VAS)

1.90±0.8

2.30±1.0

P=0.015

Pain reduction satisfaction (VAS)

2.1±0.8

1.74±0.92

P<0.001

Cumulative misoprostol dose (µg)

1114.81±328.30

1235.71±387.30

P<0.001

-0.43±1.89

-0.13±0.87

P=0.130

14.09±3.6

14.66±3.8

P=0.350

Characteristics
Induction-to–abortion time (hours)

Hemoglobin decrease (mg/dl)
Size of the retained products of
conception by ultrasound (mm)

P-value

VAS: visual analog scale
µg: microgram
mg/dl: milligram/deciliter
mm: millimeter

Table 3. Comparison of cumulative pethidine dosage between 2 groups
Cumulative Pethidine
dosage
25 mg

Therapeutic diclofenac (n)

Prophylactic diclofenac (n)

P-value

34

27

-

50 mg

9

0

Total

43

27

Χ2 =6.485
P=0.011

n: number of the participants

Discussion
This study revealed that the severity of pain, which
was measured by a visual analog scale, residual of
conceived products, hospitalization days, and the total
misoprostol dosage were significantly lower in groups
receiving diclofenac before the pain begins.
Both physical and psychological pain during the
abortion process are experienced and described by
women (16). It is imperative to support women who are
undergoing an induced abortion, especially when the
fetus is not viable (17, 18). Therefore, there is a clear
need for standardized and evidence-based regimens for
the management of pain associated with a medical
abortion (19).
Currently, few studies have examined pain management during induced medical abortion (7, 14, 19).
Heterogeneity of existing data limits comparison. Therefore, further research is needed to determine the optimal
analgesia regimens for second trimester induced medical
abortion (9). NSAIDs are used to relieve the symptoms
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in various conditions characterized by acute pain such as
induced first and second-trimester medical abortion.
Although theoretically prostaglandin is inhibited by
NSAIDs, studies have shown that co-treatment with
NSAID and misoprostol does not attenuate the efficacy
of misoprostol (20-22). In our study, prophylactic use of
diclofenac did not interfere with the action of misoprostol to induce abortion, while significantly shortened
induction-to-abortion interval, lowered cumulative dosage of misoprostol, and shortened hospitalization length. In another study, diclofenac significantly lowered
the induction-to-abortion time, the need for opioid
analgesic use, cumulative misoprostol dosage, and hemoglobin decrease during the first trimester induced
medical abortion (22).
NSAIDs eventually reduced the need for opiate
injections when used for pain relief during second
medical abortion (20). In our study, the pain was a
common experience between two randomized allocated
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groups, who either received prophylactic or therapeutic
diclofenac for pain relief. Prophylactic diclofenac administration resulted in a more satisfactory pain reduction
experience and decreased pain intensity more vigorously. Additionally, in group one who received prophylactic diclofenac (with the first dose of misoprostol),
the cumulative dose of opioid usage was significantly
lower compared to those who received therapeutic
diclofenac (with pain onset).
There was no significant difference between the two
groups in terms of the size of the retained products of
conception by ultrasound. It may be partly due to
performing an ultrasound exam the day after abortion
per hospital protocol, which was pretty soon to evaluate
complete abortion.
The volume of blood loss was higher in patients who
receive NSAIDs for pain relief during a medically
induced abortion in comparison with those who received
other analgesics, but this finding was not supported by
the changes in hemoglobin levels (20). In our study, the
volume of blood loss was higher in group one than group
two based on changes in hemoglobin levels checked on
admission and before the women were discharged, but
the difference was not significant. It needs to be studied
in a larger group of patients to realize whether the

difference between blood losses in these two methods of
administration could be considerable.

Conclusion
The present study suggests that prophylactic administration of diclofenac acts better than therapeutic dose
on relieving the pain, shortening the induction-toabortion interval, lowering the total misoprostol usage,
and minimizing the opioid analgesic injections in
medical abortion and increasing satisfaction rate in
patients when diclofenac was used prophylactically.
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